Why the Best Publish in Oncotarget

Oncotarget, a peer review journal for oncologists, is one of the most highly-regarded peer review journals to be published in. Currently, this journal is sought out by those who are dedicated to the study of the cure for cancer, cancer prevention, new and innovative treatments, and areas of medicine and science that are related to the elderly population. This journal, started by Dr. Mikhail Blagosklonny, is also highly-regarded for its adherence to guidelines for best practices, as well as to ensuring that credit is given to whom it is due.

Regardless of whether or not the individual making a submission is an author, editor, or reviewer, they are all held to the standards of COPE, for the Conduct of Best Practices. This journal like many others gets hundreds of submissions, and its editors are required to review them one-by-one for their technical merit, quality of data, and the importance of the scientific community as well. Those who submit to this journal are free to do so regardless of their race, creed, color, or sexual orientation, adding to the professionalism an ability to raise the bar in all areas of its research and publications. Check the journal at SCImago Journal & Country Rank.

The complexity of tumor development and other aspects of cancer research have made it the “go to” resource for those who wish to be expert researchers in cancer and related areas of medicine.  This journal is dedicated to not only the study and prevention of cancer, but it is also committed to publishing the latest information regarding neuroscience, endocrinology, cardiology, cell biology, pharmacology and many other areas.

There are numerous authors that have made submissions to Oncotarget that have made viable contributions to the field of medicine, but also to the related research in related fields. Those who wish to read the latest on cancer research should take the time to read and research Oncotarget. Download output styles at Endnote.com

One Reply to “Why the Best Publish in Oncotarget”

  1. Dr. Mikhail Blagosklonny has been committed to disease examine, and the investigation of Rapamycin and its impacts on growth cells. This is another motivation behind why Oncotarget keeps on ascending in fame. It is quite necessary for essayclick to have an outstanding deal with them which might not be going for long too.

Leave a Reply

Your email address will not be published. Required fields are marked *